Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Drug Recalls For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Maxidex (dexamethasone ophthalmic suspension), 0.1%, Alcon, NDA 13-422/S-035 CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION) Injection 1GM BASE/VIAL MAXIPIME BRISTOL MYERS SQUIBB 050679 CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION) Injection 2GM BASE/VIAL MAXIPIME BRISTOL MYERS SQUIBB 050679 CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION) Injection 500MG BASE/VIAL MAXIPIME BRISTOL MYERS SQUIBB | MAXIPIME (cefepime hydrochloride) Powder for Injection, Bristol-Myers Squibb, Labeling Revision | Cefepime Hydochloride Injection, ACS Dobfar, Approval | Cefepime Injection, Baxter Healthcare Corp., Approval ^ FDA's latest approval appears at the bottom of this list. ^   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News © 2008 Betterchem.com